GlassScriptPhysician profile
Davdatt V Patel
NPI 1114986601
$3,084.34
in general payments reported to CMS, 2019-2025
23 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $398 · 2022: $404 · 2023: $605 · 2024: $674 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839 · Travel and Lodging: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,838.50 |
| Travel and Lodging | $443.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $443.97 | 2025 | Clottriever Bold Catheter |
| Janssen Pharmaceuticals, INC | $320.03 | 2021-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $312.55 | 2024-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $292.45 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.00 | 2021-2024 | Jardiance |
| Medtronic, INC. | $266.01 | 2021-2023 | Micra |
| Amgen INC. | $254.53 | 2022-2025 | Repatha, Repatha |
| Abbott Laboratories | $237.50 | 2022-2025 | Xience Skypoint, Cardiomems, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.84 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $123.58 | 2022-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $83.50 | 2022-2025 | |
| Boston Scientific Corporation | $79.83 | 2021-2025 | General - Therapies |
| Kiniksa Pharmaceuticals, LTD. | $37.20 | 2023 | Arcalyst |
| Zoll Circulation INC | $30.64 | 2021 | |
| Edwards Lifesciences Corporation | $26.78 | 2024 | Sapien 3 Ultra Resilia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $24.59 | 2024 | Arcalyst |
| Pfizer INC. | $24.46 | 2022 | |
| Recor Medical INC | $24.25 | 2025 | Paradise Ultrasound Renal Denervation System |
| Scpharmaceuticals INC. | $18.51 | 2025 | |
| Esperion Therapeutics, INC. | $17.39 | 2025 | Nexletol |
| Chiesi USA, INC. | $17.37 | 2023 | Kengreal, Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $17.03 | 2024 | Camzyos |
| Cardiovascular Systems INC. | $13.33 | 2023 | Diamondback Peripheral |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davdatt Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.